We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BRKR Shares Climb After Securing New Orders for Its NMR Systems
Read MoreHide Full Article
Key Takeaways
Bruker received $10M in new NMR instrumentation orders from NYSBC, Delaware, and Northwestern.
BRKR's systems, backed by NIH and NSF funding, will be delivered and installed in 2026.
The new orders strengthen Bruker's BioSpin segment and lifted shares 6.2% to $36.98.
Bruker Corporation (BRKR - Free Report) recently received new orders for advanced Nuclear Magnetic Resonance (“NMR”) instrumentation from the New York Structural Biology Center (“NYSBC”), the University of Delaware and Northwestern University. The NMR systems are supported by the National Institutes of Health (“NIH”) and the National Science Foundation (“NSF”).
The aggregate value of these three federally funded NMR orders is approximately $10 million, and they are expected to be delivered and installed next year. The latest development is expected to bolster the company’s BioSpin segment.
BRKR Stock’s Likely Trend Following the News
Since the announcement, shares of Bruker have risen 6.2%, finishing last Friday’s session at $36.98.
Bruker is strategically progressing with its BioSpin’s products that have specific applications in structural proteomics, drug discovery, research, and food and materials science fields, providing customers with the ability to ascertain the structure, dynamics, and function of specific molecules, such as proteins, as well as characterize and determine the composition of mixtures. Accordingly, the latest orders for its NMR systems should continue to boost the market sentiment surrounding BRKR stock.
Bruker has a market capitalization of $5.28 billion. Going by the Zacks Consensus Estimate, the company’s 2025 earnings are expected to increase 2.7%.
More on Bruker’s NMR Order From NYSBC
NYSBC ordered an NIH-funded Multifield NMR Relaxometry System. This advanced relaxometry system will be the first of its kind in North America, serving a consortium of nine research institutions in New York State as well as the broader national community through the NIH-funded Center on Macromolecular Dynamics by NMR spectroscopy. The system consists of a fast NMR sample shuttle system, a magnetic tunnel, and an electromagnetic field cycling coil (FCC), all mounted on a 700 MHz superconducting NMR magnet.
More on BRKR’s NMR Order From the University of Delaware
At the University of Delaware, the Department of Chemistry and Biochemistry has ordered a 600 MHz Dynamic Nuclear Polarization (DNP) NMR spectrometer, funded by the NSF Major Research Instrumentation program. This instrument will serve over 25 research groups at the University of Delaware and 12 collaborating institutions, supporting projects that range from understanding the molecular basis of disease to developing new materials and sustainable technologies. The new spectrometer’s enhanced sensitivity will enable investigations of complex biological and engineered systems, including intact cells, protein assemblies, polymers, pharmaceutical formulations, and catalysts.
Image Source: Zacks Investment Research
More on Bruker’s NMR Order From Northwestern University
At Northwestern University, the Integrated Molecular Structure Education and Research Center (“IMSERC”) recently ordered an 800 MHz NMR spectrometer. The instrument will benefit over 15 NIH-funded research groups and the broader Chicago research community, including the Chicago Biomedical Consortium. Key research applications include high-resolution biomolecular NMR for drug discovery, protein-ligand interactions, neurodegenerative disease research, regenerative medicine, and advanced materials development.
Industry Prospects Favor BRKR
Per a report by Verified Market Reports, the NMR systems market revenues totaled $2.50 billion in 2024 and are estimated to reach $4.00 billion by 2033, at a CAGR of 5.5% from 2026 to 2033. The primary drivers of the NMR Systems market include the rising demand for advanced analytical solutions across various industries.
The pharmaceutical sector, in particular, is witnessing an upsurge in the use of NMR for drug discovery and development, necessitating high-precision instruments. Furthermore, growing research activities in academic institutions and laboratories are propelling the demand for NMR systems.
Another Development by BRKR
Bruker recently signed multiple new contracts and framework agreements for its explosives and chemical trace detection solutions, accessories, consumables, and service offerings. Finalized throughout 2025, these agreements represent a total order volume of over $27 million year to date, supporting customers in the aviation security and defense industry to enhance threat detection capabilities.
BRKR Stock Price Performance
Over the past three months, Bruker’s shares have lost 10.4% compared with the industry’s 10.9% decline.
BRKR’s Zacks Rank & Key Picks
Bruker currently has a Zacks Rank #5 (Strong Sell).
Masimo’s shares have jumped 18.9% in the past year. MASI’s earnings beat estimates in each of the trailing four quarters, the average surprise being 13.8%.
Shares of Phibro have surged 76.5% in the past year compared with the industry’s 3.4% growth. PAHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 27.9%.
Shares of Boston Scientific have rallied 16.7% in the past year compared with the industry’s 5.2% growth. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.1%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
BRKR Shares Climb After Securing New Orders for Its NMR Systems
Key Takeaways
Bruker Corporation (BRKR - Free Report) recently received new orders for advanced Nuclear Magnetic Resonance (“NMR”) instrumentation from the New York Structural Biology Center (“NYSBC”), the University of Delaware and Northwestern University. The NMR systems are supported by the National Institutes of Health (“NIH”) and the National Science Foundation (“NSF”).
The aggregate value of these three federally funded NMR orders is approximately $10 million, and they are expected to be delivered and installed next year. The latest development is expected to bolster the company’s BioSpin segment.
BRKR Stock’s Likely Trend Following the News
Since the announcement, shares of Bruker have risen 6.2%, finishing last Friday’s session at $36.98.
Bruker is strategically progressing with its BioSpin’s products that have specific applications in structural proteomics, drug discovery, research, and food and materials science fields, providing customers with the ability to ascertain the structure, dynamics, and function of specific molecules, such as proteins, as well as characterize and determine the composition of mixtures. Accordingly, the latest orders for its NMR systems should continue to boost the market sentiment surrounding BRKR stock.
Bruker has a market capitalization of $5.28 billion. Going by the Zacks Consensus Estimate, the company’s 2025 earnings are expected to increase 2.7%.
More on Bruker’s NMR Order From NYSBC
NYSBC ordered an NIH-funded Multifield NMR Relaxometry System. This advanced relaxometry system will be the first of its kind in North America, serving a consortium of nine research institutions in New York State as well as the broader national community through the NIH-funded Center on Macromolecular Dynamics by NMR spectroscopy. The system consists of a fast NMR sample shuttle system, a magnetic tunnel, and an electromagnetic field cycling coil (FCC), all mounted on a 700 MHz superconducting NMR magnet.
More on BRKR’s NMR Order From the University of Delaware
At the University of Delaware, the Department of Chemistry and Biochemistry has ordered a 600 MHz Dynamic Nuclear Polarization (DNP) NMR spectrometer, funded by the NSF Major Research Instrumentation program. This instrument will serve over 25 research groups at the University of Delaware and 12 collaborating institutions, supporting projects that range from understanding the molecular basis of disease to developing new materials and sustainable technologies. The new spectrometer’s enhanced sensitivity will enable investigations of complex biological and engineered systems, including intact cells, protein assemblies, polymers, pharmaceutical formulations, and catalysts.
Image Source: Zacks Investment Research
More on Bruker’s NMR Order From Northwestern University
At Northwestern University, the Integrated Molecular Structure Education and Research Center (“IMSERC”) recently ordered an 800 MHz NMR spectrometer. The instrument will benefit over 15 NIH-funded research groups and the broader Chicago research community, including the Chicago Biomedical Consortium. Key research applications include high-resolution biomolecular NMR for drug discovery, protein-ligand interactions, neurodegenerative disease research, regenerative medicine, and advanced materials development.
Industry Prospects Favor BRKR
Per a report by Verified Market Reports, the NMR systems market revenues totaled $2.50 billion in 2024 and are estimated to reach $4.00 billion by 2033, at a CAGR of 5.5% from 2026 to 2033. The primary drivers of the NMR Systems market include the rising demand for advanced analytical solutions across various industries.
The pharmaceutical sector, in particular, is witnessing an upsurge in the use of NMR for drug discovery and development, necessitating high-precision instruments. Furthermore, growing research activities in academic institutions and laboratories are propelling the demand for NMR systems.
Another Development by BRKR
Bruker recently signed multiple new contracts and framework agreements for its explosives and chemical trace detection solutions, accessories, consumables, and service offerings. Finalized throughout 2025, these agreements represent a total order volume of over $27 million year to date, supporting customers in the aviation security and defense industry to enhance threat detection capabilities.
BRKR Stock Price Performance
Over the past three months, Bruker’s shares have lost 10.4% compared with the industry’s 10.9% decline.
BRKR’s Zacks Rank & Key Picks
Bruker currently has a Zacks Rank #5 (Strong Sell).
Some better-ranked stocks in the broader medical space are Masimo (MASI - Free Report) , Phibro Animal Health (PAHC - Free Report) and Boston Scientific (BSX - Free Report) . While Masimo and Phibro sport a Zacks Rank #1 (Strong Buy) each, Boston Scientific carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Masimo’s shares have jumped 18.9% in the past year. MASI’s earnings beat estimates in each of the trailing four quarters, the average surprise being 13.8%.
Shares of Phibro have surged 76.5% in the past year compared with the industry’s 3.4% growth. PAHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 27.9%.
Shares of Boston Scientific have rallied 16.7% in the past year compared with the industry’s 5.2% growth. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.1%.